BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 23822989)

  • 1. Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review.
    Rufini V; Treglia G; Castaldi P; Perotti G; Giordano A
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):122-33. PubMed ID: 23822989
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of 123I-MIBG SPECT-CT and 18F-DOPA PET-CT in the evaluation of patients with known or suspected recurrent paraganglioma.
    Rufini V; Treglia G; Castaldi P; Perotti G; Calcagni ML; Corsello SM; Galli G; Fanti S; Giordano A
    Nucl Med Commun; 2011 Jul; 32(7):575-82. PubMed ID: 21471850
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas.
    Rufini V; Treglia G; Perotti G; Giordano A
    Hormones (Athens); 2013; 12(1):58-68. PubMed ID: 23624132
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma.
    Ilias I; Yu J; Carrasquillo JA; Chen CC; Eisenhofer G; Whatley M; McElroy B; Pacak K
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4083-7. PubMed ID: 12970267
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic status determines
    Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 6-18F-fluorodopamine PET with 123I-metaiodobenzylguanidine and 111in-pentetreotide scintigraphy in localization of nonmetastatic and metastatic pheochromocytoma.
    Ilias I; Chen CC; Carrasquillo JA; Whatley M; Ling A; Lazúrová I; Adams KT; Perera S; Pacak K
    J Nucl Med; 2008 Oct; 49(10):1613-9. PubMed ID: 18794260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index.
    Lin M; Wong V; Yap J; Jin R; Leong P; Campbell P
    Clin Imaging; 2013; 37(6):1084-8. PubMed ID: 24035263
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
    King KS; Chen CC; Alexopoulos DK; Whatley MA; Reynolds JC; Patronas N; Ling A; Adams KT; Xekouki P; Lando H; Stratakis CA; Pacak K
    J Clin Endocrinol Metab; 2011 Sep; 96(9):2779-85. PubMed ID: 21752889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of 6-[18F]fluorodopamine positron emission tomography in the localization of adrenal pheochromocytoma associated with von Hippel-Lindau syndrome.
    Kaji P; Carrasquillo JA; Linehan WM; Chen CC; Eisenhofer G; Pinto PA; Lai EW; Pacak K
    Eur J Endocrinol; 2007 Apr; 156(4):483-7. PubMed ID: 17389464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of [68Ga]DOTANOC PET/computed tomography and [131I]MIBG scintigraphy in the management of patients with pheochromocytoma and paraganglioma: a prospective study.
    Singh D; Shukla J; Walia R; Vatsa R; Paul N; Chhabra A; Nahar U; Singh H; Kumar R; Bhansali A; Rai Mittal B
    Nucl Med Commun; 2020 Oct; 41(10):1047-1059. PubMed ID: 32732602
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.
    Maurice JB; Troke R; Win Z; Ramachandran R; Al-Nahhas A; Naji M; Dhillo W; Meeran K; Goldstone AP; Martin NM; Todd JF; Palazzo F; Tan T
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1266-70. PubMed ID: 22526961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The evidence-based role of catecholaminergic PET tracers in Neuroblastoma. A systematic review and a head-to-head comparison with mIBG scintigraphy.
    Piccardo A; Treglia G; Fiz F; Bar-Sever Z; Bottoni G; Biassoni L; Borgwardt L; de Keizer B; Jehanno N; Lopci E; Kurch L; Massollo M; Nadel H; Roca Bielsa I; Shulkin B; Vali R; De Palma D; Cecchin D; Santos AI; Zucchetta P
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):756-767. PubMed ID: 37962616
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical, Diagnostic, and Treatment Characteristics of
    Jha A; de Luna K; Balili CA; Millo C; Paraiso CA; Ling A; Gonzales MK; Viana B; Alrezk R; Adams KT; Tena I; Chen A; Neuzil J; Raygada M; Kebebew E; Taieb D; O'Dorisio MS; O'Dorisio T; Civelek AC; Stratakis CA; Mercado-Asis L; Pacak K
    Front Oncol; 2019; 9():53. PubMed ID: 30854332
    [No Abstract]   [Full Text] [Related]  

  • 19. Diagnostic value of 18F-FDG PET/CT in paediatric neuroblastoma: comparison with 131I-MIBG scintigraphy.
    Dhull VS; Sharma P; Patel C; Kundu P; Agarwala S; Bakhshi S; Bhatnagar V; Bal C; Kumar R
    Nucl Med Commun; 2015 Oct; 36(10):1007-13. PubMed ID: 26049371
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (68)Ga-DOTATATE and (18)F-FDG PET/CT in Paraganglioma and Pheochromocytoma: utility, patterns and heterogeneity.
    Chang CA; Pattison DA; Tothill RW; Kong G; Akhurst TJ; Hicks RJ; Hofman MS
    Cancer Imaging; 2016 Aug; 16(1):22. PubMed ID: 27535829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.